A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

ClinicalTrials.gov ID: NCT02024607

Public ClinicalTrials.gov record NCT02024607. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan.

Study identification

NCT ID: NCT02024607
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Enrollment: 495 participants

Conditions and interventions

Conditions

Advanced Gastrointestinal Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2013
Primary completion: Feb 28, 2019
Completion: Oct 31, 2019
Last update posted: Nov 14, 2023

2014 – 2019

United States locations

U.S. sites: 14
U.S. states: 8
U.S. cities: 14

Facility	City	State	ZIP	Site status
Mayo Clinic Campus in Arizona	Phoenix	Arizona	85054	—
Florida Cancer Specialists	Fort Myers	Florida	33916	—
Emory University Winship Cancer Institute	Atlanta	Georgia	30322	—
Parkview Research Center	Fort Wayne	Indiana	46845	—
Indiana University Health Goshen Center for Cancer Care	Goshen	Indiana	46526	—
Indiana University Simon Cancer Center	Indianapolis	Indiana	46202	—
Indiana University Health Arnett Hospital	Lafayette	Indiana	47905	—
Indiana University Health Ball Memorial Hospital	Muncie	Indiana	47303	—
Mayo Clinic	Rochester	Minnesota	55901	—
Oncology Hematology Care, Inc.	Cincinnati	Ohio	45242	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
Institute for Translational Oncology Research, Greenville Health System	Greenville	South Carolina	29605	—
Tennessee Oncology - Chattanooga	Chattanooga	Tennessee	37404	—
Tennessee Oncology - Nashville	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02024607, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 14, 2023 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02024607 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →